eligibility_summary
Eligible adults 18–56 with diagnosed autoimmune disease, adequate organ function, and ability to consent. Exclusions: current or past active malignancy, prior CD19-targeted therapy, CAR-T, or any gene therapy, coexisting autoimmune disease requiring treatment, pregnancy or breastfeeding, or any other investigator-determined unsuitability.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
NCT06661811 tests CAR-T cell therapy for B cell–related autoimmune diseases. Intervention: autologous, gene‑modified T cells expressing a chimeric antigen receptor (CAR) directed against B‑cell antigens (target not specified). Mechanism: CAR‑T cells recognize and kill pathogenic B cells, aiming to deplete autoreactive B cells and their plasma‑cell precursors, reduce autoantibody production, and curb B cell antigen presentation to T cells, thereby dampening downstream T‑cell activation and inflammatory cytokine release and enabling immune reconstitution/drug‑free remission. Targets: B cells/plasma‑lineage cells and B–T cell interaction pathways.